ViiV Healthcare’s long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJM February 23, 2026 Final data from LATITUDE study show switch to long-acting injectable treatment reduced the risk of virological failure by nearly half for study participants through 48 weeks, compared to those continuing on daily oral therapy
Options Announces 15 Consecutive Years of SOC Compliance, Underlying Its Commitment to Delivering Secure Reliable Solutions February 23, 2026 Options Technology (Options), the leading provider of IT infrastructure to global financial institutions, today announced that it has achieved SOC compliance for the 15th consecutive year, adhering to Type 2 SOC 1 & ISAE 3402, Type 2 SOC 2, and Type 2 SOC 3 standards. Danny Moore, President and CEO at Options said, “From the [...]
Westlake Epoxy Expands Distribution Relationship with Brenntag to India February 23, 2026 Westlake Corporation (NYSE: WLK) today announced that Westlake Epoxy will expand its long‑standing distribution relationship with Brenntag to South and West India. The agreement builds on a successful collaboration across Europe, North and South America, and Southeast Asia, extending Westlake Epoxy’s reach into one of the world’s fastest‑growing coatings, adhesives and construction markets. Under the [...]
ActiveCampaign Backs Autonomous Marketing with Results Guarantee February 23, 2026 The company becomes first in category to guarantee marketing outcomes, signaling strong platform performance & commitment to customer success
BAE Systems Announces 2025 Full Year Results February 23, 2026 Charles Woodburn, Chief Executive, said: “Our results highlight another year of strong operational and financial performance, thanks to the outstanding dedication of our employees. In a new era of defence spending, driven by escalating security challenges, we’re well positioned to provide both the advanced conventional systems and disruptive technologies needed to protect the nations we [...]
AlgoSec Posts 37% YoY New Business Growth in 2025 as Enterprises Prioritise Application-Centric Security February 23, 2026 Over 90% gross dollar retention and 37% year-over-year new business growth reflect demand for visibility across complex hybrid environments
Jensen Partners Named Recruitment Company of the Year: Investor Relations & Asset Raising at the 2026 Private Equity Wire® European Awards February 23, 2026 Recognition highlights the firm’s leadership in capital formation and investor relations recruitment across European private markets
Toshiba Showcases End-to-End Innovations Shaping What’s Next in Retail at EuroShop 2026 February 23, 2026 At EuroShop, Toshiba showcases intelligent, scalable solutions that combine AI, computer vision, and energy-efficient design to transform the future of retail.
Graphene Launches Authorised Investment Platform for Alpha Investment Office February 23, 2026 Platform delivers regulated infrastructure, custody connectivity and end-to-end investment operations to support Alpha’s growth strategy
Almirall’s 2025 Results February 23, 2026 Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial execution in Europe Almirall delivered net sales growth in 2025 of 12.4% exceeding €1bn (total of €1,108.1MM), revenue increase of 12.5% (total of €1,114.5 MM), and EBITDA growth of 20.9% (total of €232.9 MM) – in line with its guidance and its sustained growth trajectory. This revenue growth further advances Almirall’s leadership in medical dermatology driven by the strong performance of its European dermatology business (+25.6% YoY increase to a total of €608 MM). The continued strong performance of the biologics portfolio is the backbone of Almirall’s growth, with Ilumetri® net sales increasing 12.3% YoY (total of €234.4 MM), and Ebglyss® net sales increasing more than 3x YoY to a total of €110.8 MM – reflecting its strong position and growth trajectory across Europe in the second year after launch. Continued solid performance of the broad dermatology product portfolio with Wynzora® growing 30.5% YoY to a total of €33.8 MM, and Klisyri® growing 33.9% YoY to a total of €32.8 MM, further enhances Almirall’s position as trusted partner for patients and dermatologists. Almirall’s business performance fuels the advancement of a diversified and innovative R&D pipeline addressing skin diseases with high unmet need. Pipeline progress in 2025 included the start of the phase II study of the anti-IL-1RAP mAb in Hidradenitis suppurativa, the start of the phase II study of the IL-2muFc in Alopecia areata, and the approval of Jublia® in Germany and Seysara® in China. Guidance for 2026: net sales growth of 9%-12% and total EBITDA between €270 MM and €290 MM.